Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Wuxi Pharmatech (Cayman) Inc gives Q2 2014 guidance below analysts' estimates; reaffirms FY 2014 revenue guidance; updates FY 2014 EPS guidance


Wednesday, 14 May 2014 04:30pm EDT 

Wuxi Pharmatech (Cayman) Inc:Expects Q2 2014 total net revenues of $160-162 million.Expects Q2 2014 GAAP diluted earnings per ADS of $0.39-$0.41.Expects Q2 2014 Non-GAAP diluted earnings per ADS of $0.46-$0.48.Expects FY 2014 total net revenues of $660-670 million, the same as previous guidance.Expects FY 2014 GAAP diluted earnings per ADS of $1.53-$1.58.Expects FY 2014 GAAP diluted earnings per ADS of $1.73-$1.78.Expects FY 2014 Non-GAAP diluted earnings per ADS of $1.80-$1.85, including mark-to-market losses on foreign-exchange forward contracts of $0.20 per.Expects FY 2014 non-GAAP diluted earnings per ADS of $2.00-$2.05, excluding mark-to-market gains or losses on foreign-exchange forward contracts.Q2 2014 revenue of $164 million and EPS of $0.49 - Thomson Reuters I/B/E/S.FY 2014 revenue of $669 million and EPS of $1.96 - Thomson Reuters I/B/E/S. 

Company Quote

40.35
0.73 +1.84%
27 Apr 2015